# evidence from https://www.govinfo.gov/link/cfr/21/312?sectionnum=84&year=mostrecent&link-type=details

evidence from https://www.govinfo.gov/link/cfr/21/312?sectionnum=84&year=mostrecent&link-type=details is an evidence.

IRI: <https://ontology.bommaritollc.com/id/01a10f17-67b7-727a-802d-e8c4ecfefc54>

Type: [prov:Entity](http://www.w3.org/ns/prov#Entity), [evidence](https://ontology.bommaritollc.com/vocab/core/Evidence)

- `dcterms:identifier`: 21 CFR 312.84
- `dcterms:source`: [https://www.govinfo.gov/link/cfr/21/312?sectionnum=84&year=mostrecent&link-type=details](https://www.govinfo.gov/link/cfr/21/312?sectionnum=84&year=mostrecent&link-type=details)
- `prov:wasGeneratedBy`: [import.gpo\_links](https://ontology.bommaritollc.com/activity/01a10f15-aa7c-75f7-8e23-92ce8fb123d0)

## Pointing here

- Its wasDerivedFrom, from (1; `prov:wasDerivedFrom`):
  - [21 CFR 312.84 Risk-benefit analysis in review of marketing applications for drugs to treat life-threatening and severely-debilitating illnesses.](https://ontology.bommaritollc.com/id/01a0f094-c4ad-70e9-8fec-e2b1899763eb)

---
Also as: [Turtle](https://ontology.bommaritollc.com/id/01a10f17-67b7-727a-802d-e8c4ecfefc54.ttl), [JSON-LD](https://ontology.bommaritollc.com/id/01a10f17-67b7-727a-802d-e8c4ecfefc54.jsonld), [N-Triples](https://ontology.bommaritollc.com/id/01a10f17-67b7-727a-802d-e8c4ecfefc54.nt), [HTML](https://ontology.bommaritollc.com/id/01a10f17-67b7-727a-802d-e8c4ecfefc54)
Cite as: evidence from https://www.govinfo.gov/link/cfr/21/312?sectionnum=84&year=mostrecent&link-type=details. bc-ontology, release 0.1.0-rc38, 2026-10-21. https://ontology.bommaritollc.com/id/01a10f17-67b7-727a-802d-e8c4ecfefc54
Release 0.1.0-rc38, graph hash 05350a11cf9d0c42fba51e92b877115781ab65cb92afcd6b172ff9f8f4abf0bd.
